Head-to-head evidence
ALA-3000 vs BI 1569912
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
ALA-3000
Developed by Alar Pharmaceuticals
NCT06965569 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
BI 1569912
Developed by Boehringer Ingelheim
NCT06280235 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 243 participants, using the clinical MADRS depression score as its primary endpoint. However, the prespecified primary dose-response analysis was not statistically significant, so the trial provides well-controlled but inconclusive evidence of benefit.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALA-3000's landscape · BI 1569912's landscape